Invesco Dorsey Wright Healthcare Momentum ETF

Stanley Druckenmiller's Dukus Family Office Increases Stake in Natera Inc.

Wells Fargo Upgrades Celcuity to Outperform with $126 Price Target

Natera Inc. and MEDSIR Initiate Clinical Trial for HR+/HER2- Breast Cancer

NewEdge Advisors LLC Increases Stake in Boston Scientific

Guardant Health director sells 1,250 shares at $105 per share

B. Riley Securities Raises Madrigal Pharmaceuticals Target Price to $670

Celcuity Inc. Announces Positive Phase 3 Clinical Trial Results for Gedatolisib in Breast Cancer

Guardant Health Inc. collaborates with Trial Library to enhance cancer clinical trial accessibility

Nebula Research Increased Stake in Insmed Inc.

Guardant Health's CTO Darya Chudova Sells 22,935 Shares

Guardant Health Inc executive Kalia Kumud sold 2,000 shares

Guardant Health Director Disposes of Company Common Stock

Natera Announces Signatera MRD Test as Prognostic Biomarker for Breast Cancer Recurrence Risk

Cerity Partners LLC Increases Stake in Natera, Inc.

Insmed Director Sells $4.1M in Shares, Rothschild Upgrades to Buy

Natera Director Chapman Reports Disposition of Common Stock

Celcuity Inc. Director Sells Common Stock

Insmed to Present Data on Treprostinil and Brensocatib at European Respiratory Society Congress

Guardant Health Launches Liquid Biopsy Service in Italy Based on Guardant360® CDx

Hood River Capital Management LLC Increases Holdings in Guardant Health

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

MDGL

Paul A. Friedman, a director and 10% owner of Madrigal Pharmaceuticals, sold 24,800 shares for $13,694,157 on December 10, 2025. The sales were part of a Rule 10b5-1 trading plan adopted in September 2025. Post-sale, Friedman holds 187,164 shares directly and 655,540 shares indirectly through SQN LLC.

TradingView

Madrigal Pharma

MADRIGAL PHARMACEUTICALS Director Sells Shares Worth Over $13 Million

Paul A. Friedman, Director at Madrigal Pharmaceuticals Inc., reported the sale of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news is for informational purposes and not financial advice.

Reuters

Madrigal Pharmaceuticals Director Paul A. Friedman Reports Sale of Common Shares

Rebecca Taub, Director at Madrigal Pharmaceuticals Inc., has reported the disposal of common shares of the company. This information was published via EDGAR by Madrigal Pharmaceuticals and is available for public access. The news is generated by Public Technologies using AI and is intended for informational purposes only.

Director Rebecca Taub Reports Disposal of Madrigal Pharmaceuticals Common Shares

NTRA

Natera Inc. and MEDSIR have launched the MiRaDoR phase II clinical trial for HR+/HER2- breast cancer, using Natera's Signatera Genome technology to evaluate treatment effectiveness. The trial aims to set a new standard in precision oncology by assessing treatment combinations' ability to reduce circulating-tumor DNA. Supported by F. Hoffman-La Roche Ltd., the trial is enrolling patients across multiple sites, with plans for expansion in Europe.

Natera

Natera and MEDSIR Launch MiRaDoR Trial in HR+/HER2- Breast Cancer

NewEdge Advisors LLC increased its stake in Boston Scientific Corporation by 14.1% in Q2, owning 109,313 shares valued at $11.74 million. Other major investors like Norges Bank and Vanguard Group also adjusted their positions. Insiders sold significant shares recently. Boston Scientific's Q3 earnings exceeded expectations with a 20.3% revenue increase year-over-year. Analysts have raised price targets, indicating positive growth prospects for the company.

Market Beat

Boston Scientific

NewEdge Advisors LLC Raises Stock Position in Boston Scientific Corporation $BSX

Guardant Health Director Medina Manuel Hidalgo sold 1,250 shares at $105 each, totaling $131,250. This sale reduced his position by 61.06%. The stock traded down 0.6% to $102.62. Analysts have given the stock a "Moderate Buy" rating with a target price of $80.86. Institutional investors have adjusted their positions in the company.

Guardant Health

Guardant Health (NASDAQ:GH) Director Sells $131,250.00 in Stock

Sheena Jonathan Director of Natera Inc [NTRA] filed a Form 4 on December 11, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date12/9/25TransactionExercise(1) Shares4,436Price$9.29Value$41,210Ending Holdings: 273,660 (227,096 - Direct, 46,564 - Indirect)(1) Exercised 2.2 years before expiration date.For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Dir Sheena Acquires 4,436 Of Natera Inc [NTRA]

Boston Scientific Corp.'s stock fell 1.02% to $91.75 on Thursday, underperforming compared to competitors like Abbott Laboratories, which rose 0.60%. The stock is 16.21% below its 52-week high. Trading volume was higher than average, at 11.1 million shares.

Dow Jones

Abbott Laboratories

Boston Scientific Corp. Stock Underperforms Thursday When Compared To Competitors

Madrigal Pharmaceuticals appoints Rita Thakkar as Senior VP and Chief Accounting Officer, effective Jan 12, 2026. Her compensation includes a $450,000 base salary, a performance bonus, and an equity award valued at $1,932,000. In case of qualifying terminations, she will receive salary continuation, bonus, accelerated equity vesting, and health benefits. If termination occurs within a year of a change of control, she gets a lump sum payment, full equity vesting, and health benefits.

Madrigal Pharmaceuticals Sets New Compensation Package for Chief Accounting Officer

B. Riley Securities has increased the price target for Madrigal Pharmaceuticals to $670.00 per share, up from the previous target of $560.00.1On December 10, 2025, Madrigal Pharmaceuticals directors filed Form 144 to sell restricted shares: Paul A. Friedman for 49,600 shares and Rebecca Taub for 18,650 shares under trading plans.2

Key facts: B. Riley Raises Madrigal Price Target to $670; Directors File Form 144

Guardant Health Inc. has partnered with Trial Library to enhance access to cancer clinical trials in the U.S. by integrating genomic data with AI-powered patient matching. This collaboration aims to improve enrollment of diverse patient populations in precision oncology trials, offering new treatment opportunities and boosting participation in cancer research.

Guardant Health Partners with Trial Library to Expand Access to Cancer Clinical Trials

INSM

Nebula Research & Development LLC increased its stake in Insmed, Inc. by 985% in Q2, now holding 36,661 shares worth $3.69 million. Other investors also adjusted their positions. Insmed's stock performance showed a 52.4% revenue increase YoY, despite a Q3 EPS loss of $1.75. Analysts have given positive ratings, with price targets ranging from $135 to $215.

Insmed

Insmed, Inc. $INSM Shares Acquired by Nebula Research & Development LLC

CELC

Celcuity Inc. presented updated results from the Phase 3 VIKTORIA-1 trial at the 2025 San Antonio Breast Cancer Symposium. The trial evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR+/HER2- advanced breast cancer. Results showed improved progression-free survival and delayed deterioration in well-being compared to fulvestrant alone. The study highlighted the potential of gedatolisib regimens to offer significant benefits for patients with PIK3CA wild-type advanced breast cancer.

StockTitan

Celcuity

Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium | CELC Stock News

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing

marketscreener

Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing

03:41 AM EST, 12/11/2025 (MT Newswires) -- Darya Chudova, Chief Technology Officer, on December 08, 2025, sold 22,935 shares in Guardant Health ( GH ) for $2,417,980. Following the Form 4 filing with the SEC, Chudova has control over a total of 66,943 common shares of the company, with 12,463 shares held directly and 54,480 controlled indirectly.SEC Filing: MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

fidelity

Guardant Health Insider Sold Shares Worth $2,417,980, According to a Recent SEC Filing